Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Barnes & Thornburg's Seth Mailhot and Jason Mercer explain the FDA and HHS response and potential rulemaking that could result
January 2026: Amgen completed Phase 3 enrollment for MariTide (AMG 133) in the MARITIME-Obesity trial, with interim efficacy data expected in Q3 2026 that will position the monthly injection GLP-1/GIP antagonist as a once-monthly obesity treatment alternative
People willing to commit to longer treatment and able to tolerate possible GI side effects
Carr ER, Higgins PB, McClenaghan NH, Flatt PR, McCloskey AG (2024) MicroRNA regulation of islet and enteroendocrine peptides: physiology and therapeutic implications for type 2 diabetes
The drug is based on a molecule called semaglutide, which mimics the structure of a hormone that naturally occurs in our bodies called glucagon-like peptide 1 (GLP-1)
doi: 10.1080/17425255.2021.1925249
US$ 22.61
US$ 29.40
US$ 20.04
US$ 21.55
US$ 22.18
US$ 27.53
